The remedē system helps treat adults with moderate to severe central sleep apnoea. Credit: tommaso79 / Shutterstock.com.

Asahi Kasei company Zoll Medical has received approval from the US Food and Drug Administration (FDA) for its remedē system for conditional use with magnetic resonance imaging (MRI).

The remedē system is an implantable transvenous phrenic nerve stimulator intended to treat patients who are experiencing moderate to severe central sleep apnea (CSA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The approval for use with full-body MRI covers all models of the remedē system, encompassing both new patients adopting the remedē device and existing users.

Zoll Respicardia president Collin Anderson said: “Prior to this approval, the need for ongoing MRI was a contraindication for the remedē system and a concern for patients who were uncertain about their long-term healthcare needs.

“FDA approval to use full-body MRI on remedē patients is a significant milestone for Zoll and the remedē therapy.”

In 2017, the company received approval from the FDA for its remedē system, which automatically activates each night to stimulate a phrenic nerve in the chest.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This stimulation then sends signals to the breathing muscles (diaphragm), which consequently helps restore a more regular breathing pattern.

In 2021, the regulator approved the next-generation remedē EL-X system that integrates improved functionality with a patient-friendly design to simplify the implant procedure and offer increased device longevity for CSA patients.

Reduced size, longer average battery life, stimulation and sensing from a single lead, as well as full-night, respiration and device algorithm monitoring capabilities through DRēAM View, are some of the benefits of the remedē EL-X system.